Get the Stockscreener App
2.255
5.37%
0.115
After Hours:
2.25
-0.005
-0.22%
Prokidney Corp stock is traded at $2.255, with a volume of 913.50K.
It is up +5.37% in the last 24 hours and down -3.63% over the past month.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$2.14
Open:
$2.19
24h Volume:
913.50K
Relative Volume:
0.56
Market Cap:
$319.18M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-3.9561
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
+2.50%
1M Performance:
-3.63%
6M Performance:
+253.89%
1Y Performance:
+24.59%
1-Day Range:
$2.16
$2.285
1-Week Range:
$2.10
$2.292
52-Week Range:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.255 | 302.91M | 0 | -35.47M | -124.27M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney Corp. CEO Bruce Culleton to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Hold" by Analysts - MarketBeat
ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN
ProKidney (NASDAQ:PROK) Shares Down 7.3%Should You Sell? - MarketBeat
B of A Securities Downgrades ProKidney (PROK) - MSN
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN
ProKidney Corp. (PROK) positioned to redefine chronic kidney disease treatment, believes HC Wainwright - MSN
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance
ProKidney (PROK) price target increased by 15.10% to 6.85 - MSN
ProKidney (PROK) Price Target Increased by 15.10% to 6.85 - Nasdaq
Is ProKidney Corp. stock attractive for growth ETFsWeekly Trade Recap & Weekly High Momentum Picks - Улправда
Is ProKidney Corp. stock a buy on dipsTrade Exit Summary & Growth Focused Stock Reports - Улправда
Will ProKidney Corp. stock maintain momentum in 2025Weekly Trend Recap & Weekly Momentum Stock Picks - Улправда
Is ProKidney Corp. stock attractive for passive investors2025 Trade Ideas & AI Driven Price Forecasts - Улправда
ProKidney (NASDAQ:PROK) Stock Price Down 4.3%What's Next? - MarketBeat
Will ProKidney Corp. stock outperform tech sector in 20252025 Performance Recap & Smart Swing Trading Alerts - DonanımHaber
Aug Breakouts: Is ProKidney Corp. stock a buy on dips2025 Top Decliners & High Return Trade Opportunity Guides - Улправда
HC Wainwright Weighs in on ProKidney FY2025 Earnings - MarketBeat
ProKidney initiated with a buy at HC Wainwright - MSN
ProKidney (NASDAQ:PROK) Stock Price Up 5.2%What's Next? - MarketBeat
ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at HC Wainwright - MarketBeat
Truliant, ProKidney sales top Triad commercial transactions for week of Dec. 12 - The Business Journals
HC Wainwright & Co. Initiates Coverage of ProKidney (PROK) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target By Investing.com - Investing.com South Africa
ProKidney initiated with a Buy at H.C. Wainwright - TipRanks
HC Wainwright & Co. Initiates Coverage on ProKidney (PROK) with a Buy Rating | PROK Stock News - GuruFocus
HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target - marketscreener.com
H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target - Investing.com India
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ProKidney (NASDAQ:PROK) Trading Down 6.8%What's Next? - MarketBeat
Why ProKidney Corp. stock remains resilientJuly 2025 Earnings & Real-Time Volume Analysis - Newser
Promising Penny Stocks To Watch In December 2025 - simplywall.st
What drives ProKidney Corp stock priceCurrency Fluctuation Impact & Rapid Capital Trading Tips - earlytimes.in
ProKidney site sells Greensboro site for $6.5M less than it paid for property - The Business Journals
While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership - Yahoo Finance
ProKidney Corp. (PROK) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How ProKidney Corp. stock benefits from tech adoptionWeekly Volume Report & Smart Money Movement Alerts - newser.com
Will ProKidney Corp. stock beat EPS estimatesMarket Rally & Free Risk Controlled Daily Trade Plans - newser.com
What data driven models say about ProKidney Corp.’s futureQuarterly Market Summary & Weekly Stock Breakout Alerts - newser.com
What technical charts say about ProKidney Corp. stockJuly 2025 Levels & Low Drawdown Momentum Ideas - newser.com
What valuation multiples suggest for ProKidney Corp. stockJuly 2025 EndofMonth & Reliable Trade Execution Plans - newser.com
Is now a turning point for ProKidney Corp.Recession Risk & Fast Entry Momentum Trade Alerts - newser.com
What sentiment indicators say about ProKidney Corp. stock2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):